Insider Buying: Phio Pharmaceuticals (NASDAQ:PHIO) Director Acquires $15,189.00 in Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Director Ronald Plott bought 18,300 shares of the stock in a transaction on Monday, November 9th. The stock was purchased at an average price of $0.83 per share, for a total transaction of $15,189.00. Following the completion of the purchase, the director directly owned 60,300 shares in the company, valued at approximately $50,049. This represents a 43.57% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ronald Todd Plott also recently made the following trade(s):

• On Monday, September 28th, Ronald Plott purchased 5,000 shares of Phio Pharmaceuticals stock. The shares were purchased at an average price of $1.03 per share, with a total value of $5,150.00.
• On Wednesday, August 19th, Ronald Plott purchased 15,000 shares of Phio Pharmaceuticals stock. The stock was purchased at an average cost of $1.14 per share, for a total transaction of $17,100.00.

Phio Pharmaceuticals Stock Up 1.1%

Shares of PHIO stock traded up $0.01 on Tuesday, reaching $0.85. The company’s stock had a trading volume of 37,487 shares, compared to its average volume of 1,315,510. Phio Pharmaceuticals Corp. has a 12-month low of $0.75 and a 12-month high of $1.88. The company has a market capitalization of $9.87 million, a P/E ratio of -0.70 and a beta of 0.93. The stock’s 50 day simple moving average is $0.96 and its 200-day simple moving average is $1.08.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36). Research analysts expect that Phio Pharmaceuticals Corp. will post -1.45 EPS for the current year.

Analyst Ratings Changes

PHIO has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, August 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.